The abstract is read at the publisher; the summary is JClub's.
MobGen de novo design produced monobodies that bind the SARS-CoV-2 Spike RBD, with in silico optimization improving production yield, stability, binding affinity, and antiviral activity.
- Why it matters: Discovering antigen-specific monobodies with high affinity usually depends on screening very large randomized libraries, which can slow development against emerging viral threats.
- What they did: The MobGen computational pipeline was used to design and then in silico optimize monobodies targeting the SARS-CoV-2 Spike glycoprotein receptor binding domain.
- The result: Optimized binders showed improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, supporting MobGen as a rapid route to antibody-like antiviral molecules.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.